/ RESORCE phase III trial Regorafenib vs Placebo

Prof Bruix presented at European Society of Medical Oncology (ESMO) 18th World Congress on Gastrointestinal Cancer (WCGC) carried on in Barcelona in June the results of RESORCE (REgorafenib vs SORafenib in patients with hepatoCEllular carcinoma).

This trial is the first one to be positive in second line for patients with advanced hepatocellular carcinoma who progress on Sorafenib therapy and are tolerants to this drug.

Regorafenib showed an improvement in median overall survival of 10.6 months versus 7.8 months for placebo plus best supportive care (HR 0.63; 95% CI 0.50-0.79; p<0.001) .
Median progression-free survival was 3.1 months in Regorafenib arm vs 1.5 months in the control group (HR 0.46; 95% CI 0.37‒0.56; p

Friday July 01, 2016